Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, Matsuura K, Inoue K, Takahara S, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Sakai S, Kiga Y, Izutani T, Shiosakai K, Tsurutani J. Niikura N, et al. Among authors: aruga t. NPJ Breast Cancer. 2023 Oct 11;9(1):82. doi: 10.1038/s41523-023-00584-5. NPJ Breast Cancer. 2023. PMID: 37821514 Free PMC article.
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K. Tsurutani J, et al. Among authors: aruga t. Cancer Sci. 2015 Jun;106(6):734-739. doi: 10.1111/cas.12658. Epub 2015 Apr 9. Cancer Sci. 2015. PMID: 25786335 Free PMC article. Clinical Trial.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M. Masuda N, et al. Among authors: aruga t. Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25. Breast Cancer Res Treat. 2021. PMID: 33763789 Free PMC article. Clinical Trial.
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).
Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Tokunaga E, et al. Among authors: aruga t. Cancers (Basel). 2021 Aug 9;13(16):4008. doi: 10.3390/cancers13164008. Cancers (Basel). 2021. PMID: 34439165 Free PMC article.
Evaluation of a novel medical device for pegfilgrastim administration.
Aruga T, Doihara H, Yanagita Y, Ishida T, Yamashita T, Uehara K, Taira T, Tsurutani J, Takeshita T, Tsuyuki S, Kaneko K, Ohtake T, Yamaguchi Y, Hara Y, Saji S. Aruga T, et al. Cancer Sci. 2022 May;113(5):1763-1770. doi: 10.1111/cas.15335. Epub 2022 Mar 29. Cancer Sci. 2022. PMID: 35293085 Free PMC article.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H, Nakamura R, Masuda N, Yamashita T, Yamamoto Y, Kobayashi K, Tsurutani J, Iwasa T, Yonemori K, Tamura K, Aruga T, Tokunaga E, Kaneko K, Lee MJ, Yuno A, Kawabata A, Seike T, Kaneda A, Nishimura Y, Trepel JB, Saji S. Iwata H, et al. Among authors: aruga t. Jpn J Clin Oncol. 2023 Jan 6;53(1):4-15. doi: 10.1093/jjco/hyac166. Jpn J Clin Oncol. 2023. PMID: 36398439 Free PMC article. Clinical Trial.
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Saldajeno DP, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga RM, Tamura N, Aruga T, Ikeda K, Fukui Y, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Kawaguchi K, Toi M. Saldajeno DP, et al. Among authors: aruga t. Br J Cancer. 2024 Apr;130(6):1023-1035. doi: 10.1038/s41416-023-02527-0. Epub 2024 Jan 18. Br J Cancer. 2024. PMID: 38238427
256 results